$SYRS News
Last published 1y ago
- 1y agoSYRSRege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical TrialsPR NewswireRege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired...
- 1y agoSYRSSyros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationBusiness WireSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from
- 1y agoSYRSSyros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene OverexpressionBusiness Wire-- SELECT-MDS-1 Did Not Meet its Primary Endpoint -- -- Company to Discontinue Study, Review Full Data Set, and Evaluate Next Steps -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to
- 2y agoSYRSSyros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSYRSSyros Reports Third Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected in Mid-November -- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical
- 2y agoSYRSSyros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference
- 2y agoSYRSSyros Pharmaceuticals to Present at Upcoming Medical and Investor ConferencesBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will present additional data
- 2y agoSYRSSyros Provides Update on SELECT-AML-1 Phase 2 Clinical TrialBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will discontinue enrollment
- 2y agoSYRSSyros Pharmaceuticals, Inc. (SYRS) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSYRSSyros Reports Second Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at
- 2y agoSYRSSyros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference
- 2y agoAPREOMTHNRGMEDX+11Alltrna Announces Updates to Its Board of DirectorsPR NewswireAlltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and...
- 2y agoSYRSSyros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene OverexpressionBusiness Wire-- Three medical experts will join members of Syros' leadership team to provide an overview of HR-MDS patient management, perspectives on the current and future treatment landscape, and the opportunity for tamibarotene
- 2y agoSYRSSyros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSYRSSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateBusiness Wire– Passed Interim Futility Analysis of the Primary Endpoint in Phase 3 SELECT-MDS-1 Trial of Tamibarotene; Pivotal CR Data Expected by Mid-4Q 2024; Company to Host HR-MDS-focused Webcast Event with Medical Experts on
- 2y agoSYRSSyros to Participate in Upcoming Investor ConferencesBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will
- 2y agoSYRSSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference
- 2y agoSYRSSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug
- 2y agoSYRSSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit
- 2y agoSYRSSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateBusiness Wire-- Completed Enrollment of 190 Patients for Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial; Pivotal CR Data Expected by Mid-4Q 2024 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Also Expected in 2024
- 2y agoSYRSSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialBusiness Wire-- On track to report pivotal complete response data by mid-4Q 2024 -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of
- 2y agoSYRSSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference
- 2y agoSYRSSyros to Participate in TD Cowen 44th Annual Health Care ConferenceBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer,
- 2y agoSYRSSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of TamibaroteneBusiness Wire-- On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR Data Expected by Mid-4Q 2024 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected
- 2y agoSYRSSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten
- 2y agoSYRSSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and AzacitidineBusiness Wire-- 100% CR/CRi Rate in Patients Treated with Tamibarotene, Venetoclax and Azacitidine Compared to 70% in Patients Randomized to Treatment with Venetoclax and Azacitidine Alone -- -- Triplet Regimen Continues to
- 2y agoSYRSSyros to Participate in Upcoming Investor ConferencesBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will
- 2y agoSYRSSyros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSYRSSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateBusiness Wire– On track to report initial data from approximately 20 patients in SELECT-AML-1 trial in early December 2023 – – Expect to report pivotal CR data from SELECT-MDS-1 by mid-4Q 2024 – – Founding CEO, Nancy Simonian,
- 3y agoSYRSSyros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference
- 3y agoSYRSSyros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical CompanyBusiness Wire-- Conley Chee, CCO and CBO, to succeed Nancy Simonian, M.D. as CEO; Dr. Simonian to retire as CEO, effective December 1, 2023, and will remain on the Board of Directors -- -- Planned workforce reduction of
- 3y agoSYRSSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit
- 3y agoSYRSSyros Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateBusiness Wire-- On track to announce initial randomized data from SELECT-AML-1 trial in 4Q 2023 -- -- Expect to complete enrollment of 190 patients in SELECT-MDS-1 trial in 4Q 2023; pivotal CR data expected in 3Q 2024 -- --
- 3y agoSYRSSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit
- 3y agoSYRSSyros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference
- 3y agoSYRSSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit
- 3y agoSYRSSyros to Present at Sidoti June 2023 Virtual Small-Cap ConferenceBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer,
- 3y agoSYRSSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit
- 3y agoSYRSSyros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual MeetingBusiness Wire-- New data support further evaluation of SY-5609 for PDAC and HR+ breast cancer and demonstrate significant potential for SY-5609 in a wide range of tumor types and combinations -- -- Consistent with prior guidance,
- 3y agoSYRSSyros Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateBusiness Wire-- On track to complete enrollment of 190 patients in 4Q 2023, with pivotal complete response (CR) data from SELECT-MDS-1 expected in 3Q 2024 -- -- Amended SELECT-MDS-1 study to add overall survival as key secondary
- 3y agoSYRSSyros to Present at JMP Securities 2023 Life Sciences ConferenceBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer,
- 3y agoSYRSSyros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference
- 3y agoSYRSSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit
- 3y agoSYRSSyros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateBusiness Wire-- Commenced randomized portion of SELECT-AML-1 trial, with initial data expected in 4Q 2023 -- -- Received FDA Fast Track designation for tamibarotene for the treatment of HR-MDS -- -- On-track to complete enrollment
- 3y agoSYRSSyros to Participate in Upcoming Investor Conferences in MarchBusiness WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer,
- 3y agoSYRSSyros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference
- 3y agoSYRSSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit
- 3y agoSYRSSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic SyndromeBusiness Wire-- Currently evaluating tamibarotene in combination with azacitidine pivotal SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed HR-MDS patients with RARA gene overexpression – Syros Pharmaceuticals, Inc.
- 3y agoSYRSSyros Announces Clinical Updates and 2023 Strategic PrioritiesBusiness Wire-- Expect to Complete Enrollment in SELECT-MDS-1 Phase 3 Trial in 4Q 2023; Data Expected in 3Q 2024 -- -- On Track to Initiate Randomized Portion of SELECT-AML-1 Phase 2 Trial in 1Q 2023; Initial Data Expected 4Q 2023
- 3y agoSYRSSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSyros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200 shares of